Small-cap stocks can offer significant growth potential for investors willing to take on a higher level of risk. One such stock that has caught the attention of analysts is STAAR Surgical Company (STAA), a U.S. ophthalmic medical device firm that specializes in implantable lenses for vision correction.
Recently, Morgan Stanley resumed coverage of STAA with an Underweight rating and a $13 price target. The firm highlighted STAAR’s EVO ICL technology as impressive but noted that it remains a niche product with a limited addressable patient pool. Expansion in the U.S. and other Western markets may pose challenges, even as the company executes effectively. It was noted that the shares are trading above pre-merger levels, which was seen as somewhat surprising.
On the same day, Canaccord Genuity lowered its price target on STAA to $22 from $30.75 and maintained a Hold rating. The adjustment came after the company’s cooperation agreement with its largest shareholder, Broadwood Partners, and the rejection of the merger with Alcon. Canaccord shifted its valuation framework back to STAAR’s standalone fundamentals rather than the proposed Alcon deal price.
While STAA shows promise as an investment, some analysts believe that there are other opportunities with greater upside potential and less downside risk. For investors looking for undervalued AI stocks that could benefit from Trump-era tariffs and the onshoring trend, there are options worth exploring.
In conclusion, STAAR Surgical Company is a compelling small-cap stock worth considering for investors looking for growth opportunities. However, it’s essential to weigh the risks and potential rewards before making any investment decisions. As always, it’s crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.
